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Case Report: A Case of Diabetic Ketoacidosis Following Chikungunya Virus Infection
Illya Tolokh, Timothy Laux,* and Daniel Kim
Division of Medical Education, Department of Internal Medicine, Washington University in St. Louis, Missouri;
Barnes Jewish Hospital, St. Louis, Missouri
Abstract. Chikungunya is a mosquito-borne viral disease that has recently become endemic in the Caribbean, including
the island of Puerto Rico. We present the case of a 50-year-old Puerto Rican man who traveled to St. Louis for business
and was diagnosed with acute chikungunya virus infection with atypical features causing diabetic ketoacidosis. This case
highlights the need to keep tropical infectious diseases on the differential diagnosis in appropriate individuals and the ways
in which tropical infectious diseases can masquerade as part of common presentations.
INTRODUCTION
Chikungunya is a mosquito-borne viral infection, character-
ized by fever and acute polyarthralgias.1 There is no drug for
treatment or vaccine for prevention available.2 Chikungunya
virus is an alphavirus of the Togaviridae family that is trans-
mitted by mosquitoes of the genus Aedes (mainly Aedes
aegypti and Aedes albopictus).3 First isolated in 1952,
chikungunya has reemerged in the past decade, causing wide-
spread epidemics in 2005–2006 in the islands of the Indian
Ocean and southern India.4
There is evidence that the chikungunya virus strain that
circulated during the Indian Ocean epidemic had acquired a
mutation, which made transmission by Ae. albopictus possi-
ble.5 This species of mosquito is found in a more temperate
climate than the traditional vector Ae. aegypti. The first
locally transmitted case of chikungunya in the Americas was
on the Caribbean Island of Saint Martin in December 2013.
Since then, there have been 1,975 confirmed cases in Puerto
Rico as of August 12, 2014, and 1,100 cases in the United
States, including 272 in Florida as of October 1, 2014.6,7 Most
of the U.S. cases have been associated with travel to an
endemic area; however, 11 cases of local transmission were
reported in Florida.7
With the recent outbreak of chikungunya in the Americas,
imported cases among returning travelers in the United
States will likely continue to increase. With ongoing interest
in neglected tropical diseases, especially as some have spread
to nonendemic regions, we seek to present a case of diabetic
ketoacidosis (DKA) in a traveler with chikungunya from a
chikungunya-endemic area.
CASE REPORT
A 50-year-old Puerto Rican man with type 1 diabetes
mellitus and hyperlipidemia visiting St. Louis, MO on a busi-
ness trip presented to our hospital on the third day of his trip
complaining of 2 days of subjective fever, weakness, diffuse
myalgias, nausea, and large-volume diarrhea. He denied
recent or ongoing arthralgias. Symptoms started 1 day after
landing in the United States. He took over-the-counter acet-
aminophen (paracetamol) with some relief. He denied recent
travel outside of Puerto Rico or the United States. Additional
history revealed several mosquito bites in Puerto Rico prior to
the day of travel. In addition, he denied sick contacts, dietary
changes, or abdominal pain. Home medicines included simva-
statin 40 mg by mouth (PO) daily, insulin glargine 40 units (U)
administered subcutaneously at night, and 10 U of subcuta-
neous insulin lispro three times daily with meals. Per history,
he did not take his insulin lispro and self-reduced his insulin
glargine dose from 40 to 15 U for the 2 days prior to presen-
tation due to poor PO intake. The patient had no known
drug allergies, was single, drank alcohol socially, and denied
tobacco or illicit drug use. There was no history of travel to
west Africa. The review of systems was otherwise negative
except as noted.
Upon admission in the emergency department, the patient’s
temperature was 36.9°C, heart rate 99 beats per minute, respira-
tory rate 12 breaths per minute, blood pressure 107/69 mmHg,
and oxygen saturation 98% on room air. He was a well-
dressed, well-nourished man in mild distress, preferring to keep
his eyes closed and was speaking quietly. He had dry mucous
membranes and anicteric sclerae. Cardiac exam revealed regu-
lar rate and rhythm without jugular venous distension or lower
extremity edema. Lungs were clear to auscultation bilaterally,
without wheezing. Abdomen was soft and nondistended but
with mild tenderness to palpation in the suprapubic area.
Murphy’s sign was absent, and there was no rebound or
guarding. Lymph node exam demonstrated shotty left anterior
cervical chain lymph nodes but no other findings. Skin exami-
nation revealed no rashes, but the anterior chest wall was
mildly erythematous, possibly secondary to recent sun expo-
sure. Musculoskeletal exam, including joint exam, was within
normal limits.
In the emergency department, the patient’s laboratories
indicated DKA—blood glucose 311 mg/dL, serum ketones
5.7 mmol/L, 2 + glucose in urine, and anion gap 22 mEq/L.
His liver function tests were elevated at alanine transaminase
161 U/L, aspartate transaminase 97 U/L, and alkaline phospha-
tase 129 U/L. Complete blood cell counts revealed lymphopenia
(0.500/mm3) and thrombocytopenia (114,000/mm3). His hemo-
globin A1C was 10.0%. Electrocardiogram showed normal
sinus rhythm, and a chest radiograph showed no cardiac or
pulmonary abnormalities.
His DKA was treated with intravenous fluids and an insu-
lin drip, and he was subsequently transitioned to subcutane-
ous basal-bolus insulin regimen once his anion gap closed.
Because of the patient’s presentation with fever, nausea,
vomiting, and diarrhea, an infectious etiology for his DKA
was pursued. Viral respiratory and influenza nasopharyngeal
swab was obtained and was negative. Routine blood cultures,
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bacterial stool cultures, stool Clostridium difficile toxin, and
human immunodeficiency virus were all negative. Given his
thrombocytopenia, transaminitis, fever, myalgias, weakness,
and location in Missouri, Ehrlichia polymerase chain reac-
tion (PCR) was obtained and was negative. As the patient
lived in an area endemic for dengue and recently endemic
for chikungunya, dengue immunoglobuin M (IgM) and immu-
noglobulin G (IgG) as well as chikungunya virus reverse tran-
scription polymerase chain reaction (RT-PCR) were checked.
These laboratories were drawn on the fourth day of the
patient’s illness (and second day of his hospitalization). The
choice of testing for each disease (RT-PCR for chikungunya,
serology for dengue) was guided by availability through the
Missouri Department of Health and the home institution, as
neither disease is routinely checked at hospitals in Missouri.
Because of the lack of institutional experience, dengue serol-
ogies were sent to the Mayo clinic. In retrospect, dengue PCR
testing would have been more appropriate; however, it was
thought to be unavailable at the time.
Given his negative bacterial cultures and symptoms, a viral
syndrome was thought to be the cause of DKA. As such, he
was treated with supportive care consisting of intravenous
fluids and anti-emetics. His symptoms resolved and his labo-
ratory abnormalities improved over the course of this 3-day
inpatient hospitalization in October 2014. After tolerating an
oral diet, he was discharged on a new insulin regimen with
instructions to follow-up with his primary care physician in
Puerto Rico. Weeks after his discharge, dengue serologies
were IgG positive and IgM negative, suggestive of remote
and not acute dengue virus infection, and chikungunya RT-
PCR was positive, consistent with acute chikungunya at the
time of hospitalization.
DISCUSSION
The etiology for our patient’s DKA was likely an acute
infection with chikungunya virus. This was his first hospitali-
zation due to DKA in 15 years. He likely had local transmis-
sion of chikungunya virus in Puerto Rico the week leading
up to his airplane flight to the United States. As noted in the
retrospective analysis of the 2005–2006 Reunion Island
chikungunya outbreak, patients with diabetes were more
likely to be hospitalized than the patients that did not have
diabetes.3 Our patient’s medical history of type 1 diabetes
mellitus likely placed him at a higher risk of hospitalization.
Malaria and dengue are two of the most common systemic
illnesses reported in returning travelers. Chikungunya has
received increasing recognition in the Western Hemisphere.
Since the first locally transmitted case of chikungunya in 2013
in the Caribbean, the number of cases in Puerto Rico has
been growing steadily. Due to travel between Puerto Rico and
the United States, the number of imported cases in the United
States will likely increase. We suspect presentations similar to
our patient’s will become more common to returning travelers
in the United States. As such, chikungunya must be consid-
ered in travelers from Puerto Rico presenting with fever,
fatigue, gastrointestinal symptoms, and myalgias/arthralgias.
Our patient had some but not all the classic features of
acute chikungunya. Gastrointestinal symptoms of nausea,
vomiting, and diarrhea occur in up to 50% of the patients.3,8
These symptoms resolved with supportive care in our patient.
Like many viral infections, patients infected with chikungunya
virus can demonstrate lymphopenia, thrombocytopenia, and
elevated liver function tests.9 We originally attributed our
patient’s transaminitis to his statin. However, he had taken
this medicine for over a decade without issue. We now believe
this laboratory abnormality was also a manifestation of his
acute infection.
A very common feature of chikungunya virus infection is
polyarthralgias, mainly in the knee and ankle joints. Among
those acutely infected, patients developed arthralgias at rates
as high as 87–98% in some case series.10 In some patients,
arthralgias may resolve within 1 week, but 60% of patients
may develop chronic arthritis that can last up to 3 years.11
These polyarthralgias can be disabling and severe.5 Our
patient did not manifest this symptom while hospitalized, and
he denied having this symptom prior to hospitalization; it is
important to note that the patient was fluent in English, and
there were no language barriers. It is critical to recognize
arthralgias as part of the viral syndrome and provide acute
treatment with acetaminophen. Nonsteroidal anti-inflamma-
tory drugs (NSAIDs) should be avoided initially when there is
concern for dengue as it can increase the risk of bleeding.12
NSAIDs should only be used in adults once dengue has been
ruled out or when arthralgias last longer than 1–2 weeks, a
clinical manifestation not consistent with dengue.12 As serol-
ogy was performed for dengue on the fourth day of illness
instead of RT-PCR, there is a small chance that our patient’s
result was a false negative and that he may have been
coinfected with both viral diseases. There was no remaining
specimen upon which repeat testing could be performed for
PCR. In addition, as this patient already had IgG present in
the acute serum sample, a 4-fold increase in IgG antibody
titers between acute and convalescent serum would have indi-
cated an acute secondary dengue infection.12 However, we
were unable to follow up convalescent IgG titers for dengue
as he returned to Puerto Rico.
Patients should be educated that these joint pains may
persist for a long time after fever resolution and may prog-
ress to a destructive arthritis.5 There is no current treatment
or vaccine for chikungunya; however, as this pathogen is rap-
idly emerging, efforts are being made to develop a vaccine.2
Chang and other recently published a successful phase 1 clin-
ical trial of a virus-like particle vaccine.2
IgM antibody response to acute chikungunya virus infection
is detectable between days 2 and 7 after the onset of fever
with an enzyme-linked immunosorbent assay test.5 An IgG
antibody response is typically detectable 1–2 days after IgM
becomes detectable, approximately on day 7 of illness.13–15
IgG levels can persist for years whereas IgM levels can persist
for up to 3–4 months.5 Chikungunya virus infections can cause
high levels of viremia for 4–6 days after onset of symptoms
but can persist up to 12 days.9 As such, virus isolation and
nucleic acid detection by RT-PCR is possible within 7 days of
symptom onset.9 As diagnostic tests were sent on day 4 of
symptom onset, chikungunya virus RT-PCR was checked and
returned positive.
Aedes albopictus, one of chikungunya’s vectors, is common
throughout the contiguous United States.3 It is possible that
local transmission of the virus could spread outside of Florida,
where at least 11 locally transmitted cases have been reported.7
Consequently, it is critical that clinicians distinguish between
imported and locally transmitted cases. Even if there has been
no recent travel to an endemic region, those in regions with
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recently identified chikungunya cases who have consistent
physical examination findings or laboratory abnormalities
should be tested. Early recognition of local transmission could
lead to evidence-based public health measures, notably vector
control, and such interventions could prevent chikungunya
from becoming endemic to additional geographic areas.
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